A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer

Trial Profile

A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PEARL
  • Sponsors AstraZeneca; AstraZeneca AB
  • Most Recent Events

    • 01 Jun 2018 Planned number of patients changed from 440 to 650.
    • 01 Jun 2018 Planned End Date changed from 12 Jun 2020 to 31 Dec 2020.
    • 01 Jun 2018 Planned primary completion date changed from 22 Oct 2018 to 30 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top